HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions
- 1 November 2017
- journal article
- current perspective
- Published by Elsevier BV in European Journal of Cancer
- Vol. 86, 1-4
- https://doi.org/10.1016/j.ejca.2017.08.023
Abstract
No abstract availableFunding Information
- Intramural Research Program of the National Institutes of Health, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, MD, 20892 (Z1AHD008735)
This publication has 7 references indexed in Scilit:
- Comprehensive Molecular Characterization of Pheochromocytoma and ParagangliomaCancer Cell, 2017
- Targeting renal cell carcinoma with a HIF-2 antagonistNature, 2016
- On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer modelsNature, 2016
- Hypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right DirectionJNCI Journal of the National Cancer Institute, 2013
- SomaticHIF2AGain-of-Function Mutations in Paraganglioma with PolycythemiaThe New England Journal of Medicine, 2012
- HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progressionNature Reviews Cancer, 2011
- A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in PheochromocytomasPLoS Genetics, 2005